logo
  • Company
    • About
    • Careers
    • News
    • Honors & Awards
  • Solutions
    • The Galen™ Platform
      • First Read
      • Second Read
    • Ibex Precision Medicine
  • Technology
  • Media
    • Blog
    • Media Library
  • Early Adopter Program
  • Contact Us
logologo
  • Company
    • About
    • Careers
    • News
    • Honors & Awards
  • Solutions
    • The Galen™ Platform
      • First Read
      • Second Read
    • Ibex Precision Medicine
  • Technology
  • Media
    • Blog
    • Media Library
  • Early Adopter Program
  • Contact Us
  • Company
    • About
    • Careers
    • News
    • Honors & Awards
  • Solutions
    • The Galen™ Platform
      • First Read
      • Second Read
    • Ibex Precision Medicine
  • Technology
  • Media
    • Blog
    • Media Library
  • Early Adopter Program
  • Contact Us

Second Read

Diagnostics and Quality Control Application

banner
  • Home
  • Solutions
  • The Galen™ Platform
  • Second Read

The Second Read™ is an AI-based diagnostics and quality control application that helps pathologists enhance diagnostic accuracy with no impact on routine workflow. The application analyzes slides in parallel with the pathologist and alerts in case of discrepancies with high clinical significance (e.g. a missed cancer), thereby providing a safety net that reduces error rates and enables a more efficient workflow.

  • Safety net with 100% quality control
  • No impact on routine workflows
  • Easy to deploy
  • Detect more than cancer
  • Field-proven AI-based algorithm
  • Medical-grade accuracy
  • Secure web access via HTTPS
Potential missed cance
Diagnosis confirmed
Out of focus

Case study: Detecting Misdiagnosis

Ibex has deployed the first ever AI-based pathology cancer diagnosis system in a live clinical setting. The Ibex Second Read™ (SR) system was deployed in a large pathology institute to detect misdiagnosed prostate biopsies. All prostate cases are analyzed by the system and when a discrepancy with the diagnosis is detected, the case is sent back for an additional pathologist review.

  • Ibex SR system deployed in March 2018
  • Within the first week, reversed a misdiagnosis:
    • 55-year-old male
    • Original diagnosis: Benign prostatic hyperplasia (BPH)
    • Ibex analysis: Malignant
  • Direct impact on treatment: Diagnosis subsequently revised to adenocarcinoma with Gleason score 3+3

Portion of H&E image with algorithm results
(red = high probability for cancer)

Portion of confirmatory IHC (CK903) image
(unstained glands positive for adenocarcinoma)

Schedule a demo
Become an Early Adopter

©2020 Ibex Medical Analytics Ltd.All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Contact Us
  • Join Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy policy